整合素α1（ITGA1）蛋白，全稱為整合素α1亞基，常被稱為CD49a或VLA-1，與β1亞基結(jié)合形成α1β1整合素受體。這一受體廣泛分布于成纖維細(xì)胞、免疫細(xì)胞及內(nèi)皮細(xì)胞表面，通過(guò)識(shí)別細(xì)胞外基質(zhì)中的膠原和層粘連蛋白，介導(dǎo)細(xì)胞與周?chē)h(huán)境的動(dòng)態(tài)交互，調(diào)控組織重塑、炎癥反應(yīng)和血管生成。在病理狀態(tài)下，α1β1整合素活性異常與多種纖維化疾病密切相關(guān)，例如特發(fā)性肺纖維化和肝纖維化中，其過(guò)度激活會(huì)加速膠原沉積，導(dǎo)致器官功能衰竭。此外，ITGA1在腫瘤微環(huán)境中通過(guò)增強(qiáng)癌細(xì)胞黏附和侵襲能力，與乳腺癌、黑色素瘤的轉(zhuǎn)移潛能相關(guān)聯(lián)。藥物研發(fā)領(lǐng)域，早期針對(duì)整合素家族的廣譜抑制劑因脫靶效應(yīng)受限，近年轉(zhuǎn)向開(kāi)發(fā)亞基特異性靶點(diǎn)。針對(duì)α1的小分子拮抗劑已在動(dòng)物模型中顯示抑制纖維化進(jìn)展的潛力，而單克隆抗體類藥物處于臨床前優(yōu)化階段，未來(lái)或?yàn)榭估w維化及抗癌治療提供新策略。

熱銷產(chǎn)品

ITGA1 Antibody (CSB-PA011861LA01HU)

驗(yàn)證數(shù)據(jù)

Immunohistochemistry of paraffin-embedded human liver cancer using CSB-PA011861LA01HU at dilution of 1:100

Immunofluorescence staining of HepG2 cells with CSB-PA011861LA01HU at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Human Integrin alpha-1(ITGA1) ELISA kit (CSB-EL011861HU)

驗(yàn)證數(shù)據(jù)

貨號(hào)：CSB-EL011861HU

規(guī)格：96T/48T

靈敏度：0.078 ng/mL

檢測(cè)范圍：0.312 ng/mL-20 ng/mL

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.